Renata Company Profile
✉ Email this page to a colleague
What is the competitive landscape for RENATA
RENATA has nine approved drugs.
Summary for Renata
| US Patents: | 0 |
| Tradenames: | 9 |
| Ingredients: | 9 |
| NDAs: | 9 |
Drugs and US Patents for Renata
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Renata | VALSARTAN | valsartan | TABLET;ORAL | 218169-003 | Aug 5, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Renata | METOLAZONE | metolazone | TABLET;ORAL | 215616-003 | Oct 24, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Renata | RISPERIDONE | risperidone | TABLET;ORAL | 078707-003 | Dec 29, 2008 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Renata | CABERGOLINE | cabergoline | TABLET;ORAL | 220309-001 | Jun 15, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
